Skip to main content

Table 2 Relationship between expression of UCA1 expression and clinicopathological characteristics in patients with LUAD. N(%)

From: Mechanistic study of lncRNA UCA1 promoting growth and cisplatin resistance in lung adenocarcinoma

Group Total (n = 433) UCA1 P value
High expression Low expression
Gender 0.229
 Male 198 93 (46.97) 105 (53.03)  
 Female 235 124 (52.77) 111 (47.23)  
Age (year) 0.598
 > 65 224 115 (51.34) 109 (48.66)  
 ≤ 65 209 102 (48.80) 107 (51.20)  
N stage
 N0 281 142 (50.53) 139 (49.47) 0.706
 N1–3 142 69 (48.59) 73 (51.41)  
 NXa 10 6 (60.00) 4 (40.00)  
T stage
 T1–2 376 185 (49.20) 191 (50.80) 0.383
 T3–4 54 30 (55.56) 24 (44.44)  
 TXa 3 2 (66.67) 1 (33.33)  
M stage
 M0 286 137 (47.90) 149 (52.10) 0.019*
 M1 20 15 (75.00) 5 (25.00)  
 MXa 127 65 (51.18) 62 (48.82)  
Clinical stage 0.046*
 I, II 344 164 (47.67) 180 (52.32)  
 III, IV 89 53 (59.55) 36 (40.45)  
Smoking 0.434
 No 66 36 (54.55) 30 (45.45)  
 Yes 277 181 (49.32) 186 (50.68)  
Tumor location 0.217
 Superior lobe of left lung 108 61 (56.48) 47 (43.52)  
 Inferior lobe of left lung 65 28 (43.08) 37 (56.92)  
 Superior lobe of right lung 159 72 (45.28) 87 (54.72)  
 Middle lobe of right lung 17 10 (58.82) 7 (41.18)  
 Inferior lobe of right lung 84 46 (54.76) 38 (45.23)  
  1. a“X” means that the tumor could not be evaluated or measured. The clinicopathological data of these patients was not included in statistical tests
  2. *The difference was statistically significant